Jack O'Meara(@Jack_O_Meara) 's Twitter Profileg
Jack O'Meara

@Jack_O_Meara

Cofounder & CEO @OchreBio, developing medicines for liver diseases. ☘️

ID:1289960979237928960

linkhttp://www.ochre-bio.com calendar_today02-08-2020 16:27:37

2,5K Tweets

2,4K Followers

1,8K Following

Jack O'Meara(@Jack_O_Meara) 's Twitter Profile Photo

Agree. The most difficult, and perhaps thus most worthy application of AI to drug discovery is, in my view, the characterization of disease biology.

Better understanding how and when to intervene in disease, particularly chronic diseases, would unlock a lot of value for society.

account_circle
António Guterres(@antonioguterres) 's Twitter Profile Photo

A massive ground attack in Rafah would lead to an epic humanitarian disaster.

The international community must speak with one voice for an immediate humanitarian ceasefire in Gaza, the immediate & unconditional release of all hostages, and a massive surge in life-saving aid.

account_circle
Pearl Freier(@PearlF) 's Twitter Profile Photo

Two congenitally deaf children due to mutations of the otoferlin gene can now hear for the first time after being treated with Regeneron's investigational AAV gene therapy DB-OTO in CHORD clinical trial according to data presented at . fiercebiotech.com/biotech/little… $REGN

Two congenitally deaf children due to mutations of the otoferlin gene can now hear for the first time after being treated with Regeneron's investigational AAV gene therapy DB-OTO in CHORD clinical trial according to data presented at #ASGCT2024. fiercebiotech.com/biotech/little… $REGN
account_circle
Purvil(@purvil_g) 's Twitter Profile Photo

Vijay Pande Just like the last century we saw physics + engineering changing the way we live, this century we will see biology + engineering impacting the same way, potentially much bigger than the previous one

account_circle
Ryan Bethencourt(@RyanBethencourt) 's Twitter Profile Photo

'If I were to have the option of spending $3 billion on one longevity startup or 100, I'd run the experiment with 100 startups as top down rarely works as well as lots of chaotic experiments' Vinod Khosla SynBioBeta

'If I were to have the option of spending $3 billion on one longevity startup or 100, I'd run the experiment with 100 startups as top down rarely works as well as lots of chaotic experiments' @vkhosla @SynBioBeta
account_circle
Richard J Law 🚜--🇺🇦 🍉(@drrichjlaw) 's Twitter Profile Photo

Europe's lack of big tech is not due to over-regulation. It is due to being 27 countries with different rules & languages, having lower immigration than the US, & having much more risk-averse sources of funding & punishing bankruptcy laws. Nathan Benaich. How do we change this?

account_circle
Demis Hassabis(@demishassabis) 's Twitter Profile Photo

Thrilled to announce AlphaFold 3 which can predict the structures and interactions of nearly all of life’s molecules with state-of-the-art accuracy including proteins, DNA and RNA. Biology is a complex dynamical system so modeling interactions is crucial blog.google/technology/ai/…

Thrilled to announce AlphaFold 3 which can predict the structures and interactions of nearly all of life’s molecules with state-of-the-art accuracy including proteins, DNA and RNA. Biology is a complex dynamical system so modeling interactions is crucial blog.google/technology/ai/…
account_circle
Vishal Gulati (I back scientists)(@VishalGulati_) 's Twitter Profile Photo

Absolutely incredible new development.

Key noteworthy items:

1. Also launching Alphafold Server - lowering the threshold for starting working on protein protein / ligand interactions (not sure about privacy)

2. Acknowledges the safety issue head on. Not so in previous…

account_circle
Sek Kathiresan MD(@skathire) 's Twitter Profile Photo

Glad to announce the dosing of the first patient with VERVE-102 in the Heart-2 clinical trial

VERVE-102:
*in vivo base editor to permanently turn off the PCSK9 gene in liver and durably lower blood LDL-C
*delivered using Verve Therapeutics proprietary GalNAc-LNP delivery system as a…

Glad to announce the dosing of the first patient with VERVE-102 in the Heart-2 clinical trial VERVE-102: *in vivo base editor to permanently turn off the PCSK9 gene in liver and durably lower blood LDL-C *delivered using @VerveTx proprietary GalNAc-LNP delivery system as a…
account_circle
Thomas Kalil(@tkalil2050) 's Twitter Profile Photo

I am excited to announce the launch of Renaissance Philanthropy, with a phenomenal team including Kumar Garg. Our goal is to help foundations and philanthropists promote a 21st century renaissance, fueled by advances in science, technology and innovation.

account_circle